Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...
Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...
A revolutionary gene therapy treatment costing a staggering £1.65 million has been approved for NHS use, offering patients ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
Report with the AI impact on market trends - The global genomics market size is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Vertex Pharmaceuticals (VRTX – ...
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...
Pharmaceutical Technology on MSN13h
NHS England to offer Casgevy for sickle cell disease patientsThe UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback